{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:06:55Z","timestamp":1785600415398,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["20K07582"],"award-info":[{"award-number":["20K07582"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["24K10373"],"award-info":[{"award-number":["24K10373"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["24K12478"],"award-info":[{"award-number":["24K12478"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118492","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T13:58:39Z","timestamp":1756475919000},"page":"118492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Glutaminase inhibition confers antitumor effects in vitro and in vivo on tyrosine kinase inhibitors-resistant renal cell carcinoma cells by affecting vascular endothelial growth factor signaling"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9651-2371","authenticated-orcid":false,"given":"Kento","family":"Morozumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5692-8932","authenticated-orcid":false,"given":"Izumi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariyasu","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2025.118492_bib1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.32115","article-title":"Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma","volume":"145","author":"Sato","year":"2019","journal-title":"Int J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2025.118492_bib2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/cas.14440","article-title":"Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma","volume":"111","author":"Sato","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.15180","article-title":"Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations","volume":"113","author":"Morozumi","year":"2022","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11010001","article-title":"Metabolomic analysis to elucidate mechanisms of sunitinib resistance in renal cell carcinoma","volume":"11","author":"Sato","year":"2020","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.biopha.2025.118492_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/metabo14030170","article-title":"Elucidation and regulation of tyrosine kinase inhibitor resistance in renal cell carcinoma cells from the perspective of glutamine metabolism","volume":"14","author":"Morozumi","year":"2024","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2017.178","article-title":"Targeting glutamine metabolism for cancer treatment","volume":"26","author":"Choi","year":"2018","journal-title":"Biomol. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2025.118492_bib7","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1080\/15548627.2022.2062875","article-title":"Glutamine, MTOR and autophagy: a multiconnection relationship","volume":"18","author":"Bodineau","year":"2022","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.biopha.2025.118492_bib8","first-page":"356","article-title":"Glutaminase inhibition in renal cell carcinoma therapy","volume":"2","author":"Raczka","year":"2019","journal-title":"Cancer Drug Resist"},{"issue":"5","key":"10.1016\/j.biopha.2025.118492_bib9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ijc.28749","article-title":"Targeting glutamine transport to suppress melanoma cell growth","volume":"135","author":"Wang","year":"2014","journal-title":"Int J. Cancer"},{"issue":"24","key":"10.1016\/j.biopha.2025.118492_bib10","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/onc.2015.381","article-title":"ASCT2\/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer","volume":"35","author":"van Geldermalsen","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118492_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejphar.2018.07.007","article-title":"The role of ASCT2 in cancer: a review","volume":"837","author":"Liu","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib12","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118492_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-642-54490-3_12","article-title":"Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor","volume":"201","author":"Gr\u00fcllich","year":"2014","journal-title":"Recent Results Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118492_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118492_bib15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118492_bib16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118492_bib17","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.biopha.2025.118492_bib18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118492_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbrc.2021.11.043","article-title":"Glutamine deficiency induces lipolysis in adipocytes","volume":"585","author":"Okuro","year":"2021","journal-title":"Biochem Biophys. Res Commun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118492_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2018.11.033","article-title":"ATF4 deficiency promotes intestinal inflammation in mice by reducing uptake of glutamine and expression of antimicrobial peptides","volume":"156","author":"Hu","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.biopha.2025.118492_bib21","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol."},{"issue":"15","key":"10.1016\/j.biopha.2025.118492_bib22","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, Double-Blinded, Placebo-Controlled, phase II ENTRATA trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41467-020-15136-9","article-title":"A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer","volume":"11","author":"Kodama","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118492_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: tumor suppressor and metabolic regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"6441","key":"10.1016\/j.biopha.2025.118492_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau0159","article-title":"Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway","volume":"364","author":"Lee","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78833-x","article-title":"Upregulation of PI3K\/AKT\/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells","volume":"10","author":"Hamadneh","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cell.2012.02.030","article-title":"Systemic elevation of PTEN induces a tumor-suppressive metabolic state","volume":"149","author":"Garcia-Cao","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2025.118492_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020531","article-title":"Metabolic adjustments following glutaminase inhibition by CB-839 in glioblastoma cell lines","volume":"15","author":"De Los Santos-Jim\u00e9nez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2025.118492_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118492_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","article-title":"Cabozantinib: Multi-kinase inhibitor of MET, AXL, RET, and VEGFR2","volume":"211","author":"Gr\u00fcllich","year":"2018","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.118492_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3K\u03b1 inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.biopha.2025.118492_bib32","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.15252\/embj.201695518","article-title":"Role of glutamine and interlinked asparagine metabolism in vessel formation","volume":"36","author":"Huang","year":"2017","journal-title":"Embo J."},{"issue":"10","key":"10.1016\/j.biopha.2025.118492_bib33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40644-021-00392-9","article-title":"Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study","volume":"21","author":"Nikolovski","year":"2021","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1016\/j.biopha.2025.118492_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113237","article-title":"Succinate dehydrogenase and ribonucleic acid networks in cancer and other diseases","volume":"12","author":"Moreno","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7-8","key":"10.1016\/j.biopha.2025.118492_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2533\/chimia.2015.425","article-title":"Sedaxane, isopyrazam and Solatenol\u2122: novel Broad-spectrum fungicides inhibiting succinate dehydrogenase (SDH) - synthesis challenges and biological aspects","volume":"69","author":"Walter","year":"2015","journal-title":"Chimia (Aarau)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118492_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72107-2","article-title":"UQCRH downregulation promotes warburg effect in renal cell carcinoma cells","volume":"10","author":"Luo","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:59:41Z","timestamp":1772819981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"alternative-id":["S0753332225006869"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118492","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glutaminase inhibition confers antitumor effects in vitro and in vivo on tyrosine kinase inhibitors-resistant renal cell carcinoma cells by affecting vascular endothelial growth factor signaling","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118492"}}